Isako Saga1, Shunsuke Shibao1, Jun Okubo1, Satoru Osuka1, Yusuke Kobayashi1, Sachiko Yamada1, Satoshi Fujita1, Kenichi Urakami1, Masatoshi Kusuhara1, Kazunari Yoshida1, Hideyuki Saya1, Oltea Sampetrean1. 1. Division of Gene Regulation (I.S., S.S., J.O., S.O., Y.K., S.Y., S.F., H.S., O.S.) and Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan (I.S., S.S., K.Y.); Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (J.O.); Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan (S.Y.); Department of Neurosurgery, Toho University, Ohashi Hospital, Tokyo, Japan (S.F.); Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan (K.U., M.K.); Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan (H.S., O.S.).
Abstract
BACKGROUND: The metabolic preference of malignant glioma for glycolysis as an energy source is a potential therapeutic target. As a result of the cellular heterogeneity of these tumors, however, the relation between glycolytic preference, tumor formation, and tumor cell clonogenicity has remained unknown. To address this issue, we analyzed the metabolic profiles of isogenic glioma-initiating cells (GICs) in a mouse model. METHODS: GICs were established by overexpression of H-Ras(V12) in Ink4a/Arf-null neural stem cells. Subpopulations of these cells were obtained by single-cell cloning, and clones differing in extracellular acidification potential were assessed for metabolic characteristics. Tumors formed after intracranial implantation of these clones in mice were examined for pathological features of glioma and expression of glycolytic enzymes. RESULTS: Malignant transformation of neural stem cells resulted in a shift in metabolism characterized by an increase in lactic acid production. However, isogenic clonal populations of GICs manifested pronounced differences in glucose and oxygen consumption, lactate production, and nucleoside levels. These differences were paralleled by differential expression of glycolytic enzymes such as hexokinase 2 and pyruvate kinase M2, with this differential expression also being evident in tumors formed by these clones in vivo. CONCLUSIONS: The metabolic characteristics of glioma cells appear early during malignant transformation and persist until the late stages of tumor formation. Even isogenic clones may be heterogeneous in terms of metabolic features, however, suggesting that a more detailed understanding of the metabolic profile of glioma is imperative for effective therapeutic targeting.
BACKGROUND: The metabolic preference of malignant glioma for glycolysis as an energy source is a potential therapeutic target. As a result of the cellular heterogeneity of these tumors, however, the relation between glycolytic preference, tumor formation, and tumor cell clonogenicity has remained unknown. To address this issue, we analyzed the metabolic profiles of isogenic glioma-initiating cells (GICs) in a mouse model. METHODS: GICs were established by overexpression of H-Ras(V12) in Ink4a/Arf-null neural stem cells. Subpopulations of these cells were obtained by single-cell cloning, and clones differing in extracellular acidification potential were assessed for metabolic characteristics. Tumors formed after intracranial implantation of these clones in mice were examined for pathological features of glioma and expression of glycolytic enzymes. RESULTS: Malignant transformation of neural stem cells resulted in a shift in metabolism characterized by an increase in lactic acid production. However, isogenic clonal populations of GICs manifested pronounced differences in glucose and oxygen consumption, lactate production, and nucleoside levels. These differences were paralleled by differential expression of glycolytic enzymes such as hexokinase 2 and pyruvate kinase M2, with this differential expression also being evident in tumors formed by these clones in vivo. CONCLUSIONS: The metabolic characteristics of glioma cells appear early during malignant transformation and persist until the late stages of tumor formation. Even isogenic clones may be heterogeneous in terms of metabolic features, however, suggesting that a more detailed understanding of the metabolic profile of glioma is imperative for effective therapeutic targeting.
Authors: Isaac Marin-Valencia; Chendong Yang; Tomoyuki Mashimo; Steve Cho; Hyeonman Baek; Xiao-Li Yang; Kartik N Rajagopalan; Melissa Maddie; Vamsidhara Vemireddy; Zhenze Zhao; Ling Cai; Levi Good; Benjamin P Tu; Kimmo J Hatanpaa; Bruce E Mickey; José M Matés; Juan M Pascual; Elizabeth A Maher; Craig R Malloy; Ralph J Deberardinis; Robert M Bachoo Journal: Cell Metab Date: 2012-06-06 Impact factor: 27.287
Authors: Paolo E Porporato; Suveera Dhup; Rajesh K Dadhich; Tamara Copetti; Pierre Sonveaux Journal: Front Pharmacol Date: 2011-08-25 Impact factor: 5.810
Authors: Andreas Stadlbauer; Stefan Oberndorfer; Max Zimmermann; Bertold Renner; Michael Buchfelder; Gertraud Heinz; Arnd Doerfler; Andrea Kleindienst; Karl Roessler Journal: J Cereb Blood Flow Metab Date: 2019-02-07 Impact factor: 6.200